Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Bate

Showing results (11-20 of 110) with videos related to

Pageof 11
Sort By:
Drug Safety|February 23, 2018
Time Series Disturbance Detection for Hypothesis-Free Signal Detection in Longitudinal Observational DatabasesEd Whalen, Manfred Hauben, Andrew Bate
Lancet (London, England)|September 9, 2008
Abacavir and increased risk of myocardial infarctionRalph Edwards, Andrew Bate, Marie Lindquist
Drug Safety|August 26, 2017
From Big Data to Smart Data for Pharmacovigilance: The Role of Healthcare Databases and Other Emerging SourcesGianluca Trifirò, Janet Sultana, Andrew Bate
Statistical Methods in Medical Research|June 28, 2011
Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discoveryG Niklas Norén, Johan Hopstadius, Andrew Bate
Therapeutic Advances in Drug Safety|April 28, 2025
Perspective review: Will generative AI make common data models obsolete in future analyses of distributed data networks?Jeffery L Painter, Darmendra Ramcharran, Andrew Bate
Pharmacoepidemiology and Drug Safety|October 23, 2023
The futility of adverse drug event reporting systems for monitoring known safety issues: A case study of myocardial infarction with rofecoxib and other drugsFrançois Haguinet, Andrew Bate, Jens-Ulrich Stegmann
Frontiers in Drug Safety and Regulation|September 22, 2025
An industry perspective on the use of machine learning in drug and vaccine safetyJeffery L Painter, Raymond Kassekert, Andrew Bate
Frontiers in Drug Safety and Regulation|September 22, 2025
Corrigendum: An industry perspective on the use of machine learning in drug and vaccine safetyJeffery L Painter, Raymond Kassekert, Andrew Bate
Therapeutic Advances in Drug Safety|January 11, 2018
The hope, hype and reality of Big Data for pharmacovigilanceAndrew Bate, Robert F Reynolds, Patrick Caubel
Drug Safety|April 3, 2012
Defining 'surveillance' in drug safetyJeffrey K Aronson, Manfred Hauben, Andrew Bate
Pageof 11

Showing results (11-20 of 110) with videos related to

Sort By:
Pageof 11
Drug Safety|February 23, 2018
Time Series Disturbance Detection for Hypothesis-Free Signal Detection in Longitudinal Observational DatabasesEd Whalen, Manfred Hauben, Andrew Bate
Lancet (London, England)|September 9, 2008
Abacavir and increased risk of myocardial infarctionRalph Edwards, Andrew Bate, Marie Lindquist
Drug Safety|August 26, 2017
From Big Data to Smart Data for Pharmacovigilance: The Role of Healthcare Databases and Other Emerging SourcesGianluca Trifirò, Janet Sultana, Andrew Bate
Statistical Methods in Medical Research|June 28, 2011
Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discoveryG Niklas Norén, Johan Hopstadius, Andrew Bate
Therapeutic Advances in Drug Safety|April 28, 2025
Perspective review: Will generative AI make common data models obsolete in future analyses of distributed data networks?Jeffery L Painter, Darmendra Ramcharran, Andrew Bate
Pharmacoepidemiology and Drug Safety|October 23, 2023
The futility of adverse drug event reporting systems for monitoring known safety issues: A case study of myocardial infarction with rofecoxib and other drugsFrançois Haguinet, Andrew Bate, Jens-Ulrich Stegmann
Frontiers in Drug Safety and Regulation|September 22, 2025
An industry perspective on the use of machine learning in drug and vaccine safetyJeffery L Painter, Raymond Kassekert, Andrew Bate
Frontiers in Drug Safety and Regulation|September 22, 2025
Corrigendum: An industry perspective on the use of machine learning in drug and vaccine safetyJeffery L Painter, Raymond Kassekert, Andrew Bate
Therapeutic Advances in Drug Safety|January 11, 2018
The hope, hype and reality of Big Data for pharmacovigilanceAndrew Bate, Robert F Reynolds, Patrick Caubel
Drug Safety|April 3, 2012
Defining 'surveillance' in drug safetyJeffrey K Aronson, Manfred Hauben, Andrew Bate
Pageof 11